A topical combination antimicrobial ointment containing Mupirocin, a unique antibiotic derived from Pseudomonas fluorescens, and Metronidazole, a nitroimidazole antimicrobial. This combination provides broad-spectrum coverage against both aerobic Gram-positive bacteria (including MRSA) and anaerobic bacteria, making it particularly effective for mixed bacterial infections of the skin, especially those involving infected wounds, ulcers, and surgical sites where anaerobic organisms may be present. It is a first-line choice for preventing and treating secondary bacterial infections in conditions like diabetic foot ulcers, pressure sores, and post-operative wounds in the Indian clinical setting.
Adult: Apply a small amount (a thin layer) to the affected area 2 to 3 times daily. The area may be covered with a sterile gauze dressing if desired.
Note: 1. Clean and dry the affected area thoroughly with mild soap and water or saline. 2. Pat dry gently. 3. Apply a thin layer of ointment using a clean cotton swab or gloved finger. 4. Rub in gently until absorbed. 5. Wash hands before and after application. 6. Do not use occlusive dressings unless advised by a doctor.
The combination exerts a dual bactericidal/bacteriostatic action. Mupirocin inhibits bacterial protein synthesis by reversibly and specifically binding to bacterial isoleucyl-tRNA synthetase, preventing incorporation of isoleucine into protein chains. Metronidazole, after being reduced by nitroreductase enzymes in anaerobic bacteria and protozoa, forms cytotoxic compounds that damage microbial DNA, leading to strand breakage and cell death. This dual mechanism covers a wide spectrum, including aerobes (Staph, Strep) and anaerobes (Bacteroides, Clostridium).
Pregnancy: Category B (US FDA). Animal studies show no risk, but no adequate, well-controlled studies in pregnant women. Use only if potential benefit justifies potential risk to the fetus, especially in first trimester. Topical application minimizes systemic exposure.
Driving: Unlikely to affect ability to drive or use machines. However, if systemic absorption occurs (e.g., from large wounds), Metronidazole may cause dizziness or confusion.
| Warfarin and other Oral Anticoagulants | Metronidazole may potentiate anticoagulant effect by inhibiting metabolism, increasing INR and risk of bleeding. | Major |
| Alcohol and Alcohol-containing products | Metronidazole can cause a disulfiram-like reaction (flushing, tachycardia, nausea, vomiting) if ingested. Topical risk is minimal but theoretically possible with significant absorption. | Moderate |
| Lithium | Metronidazole may increase lithium serum levels, risk of toxicity. | Moderate |
| Phenytoin, Phenobarbital | May increase metabolism of Metronidazole, reducing its efficacy. | Moderate |
| Other Topical Products | Concurrent use with other topical agents (especially harsh chemicals, peeling agents) may increase local irritation. | Minor |